On 18 November 2026, 3,296 products in the SkinSenseDiary product index list propylparaben (sodium propylparaben counted separately, 30 products). It is the propyl ester of 4-hydroxybenzoic acid, used to slow the growth of microbes in a formula. The CIR amended assessment published in 2020 concluded that propylparaben is among 20 parabens that are safe in cosmetics in the practices of use and concentration described in that assessment, when the sum of parabens in a formulation does not exceed 0.8%. The SCCS opinion adopted on 30–31 March 2021 (SCCS/1623/20) concluded that propylparaben is safe as a preservative up to 0.14%.
Propylparaben (INCI: Propylparaben, CAS 94-13-3, EC 202-307-7) is the n-propyl ester of 4-hydroxybenzoic acid. It is used as a preservative and as a fragrance. CosIng ref. 37312 lists preservative and perfuming. Those labels describe a role in a formula. They are not a claim that the ingredient treats a skin disease, and the fragrance function is not an Annex III fragrance-allergen listing. On 18 November 2026, a product that names this ingredient was not marked as a fragrance allergen.
In a water-based product it is there to limit bacteria, yeasts, and moulds so the formula does not spoil in the pack. It is often paired with a shorter-chain paraben, especially methylparaben, because the two esters do not cover the same microbes equally well. It is a different ingredient from sodium propylparaben (CAS 35285-69-9), which is counted separately (30 products), and from the five parabens prohibited in Annex II.
Cherian and colleagues (International Journal of Toxicology, 2020) is the published form of the CIR final amended report. The Panel concluded that 20 of the 21 parabens in that assessment, propylparaben among them, are safe in cosmetics in the present practices of use and concentration described in the assessment when the sum of the total parabens in any formulation does not exceed 0.8%. The data were insufficient for benzylparaben. The scope is in the report: FDA VCRP data received in 2019 give propylparaben 9,034 uses, of which 7,520 are leave-on, up from 7,118 uses in 2006. A 2016 industry survey, quoted in the same report, kept the maximum concentrations of the previously reviewed parabens under 1%. The narrative’s highest figures are for other esters: methylparaben up to 0.9% in shampoos, and ethylparaben up to 0.65% in eye shadows for leave-on dermal contact. Those percentages are shares of the finished product in that survey. They are not a propylparaben-only maximum, and they are not the concentration in a reader’s jar.
Its job is preservation. It is added so bacteria, yeasts, and moulds are less able to grow in a water-containing product over the life of the pack. It does not treat acne, pigment, or wrinkles.
Formulas commonly list it with methylparaben. The shorter ester and the propyl ester are not interchangeable, and the EU cap on propylparaben is not the cap on methylparaben. The regulatory section sets the two limits out separately.
Preservative use sits well below the oils and the water. A place near the end of an INCI list does not reveal the percentage. Under Regulation (EC) No 1223/2009, Article 19(1)(g), ingredients below 1% may be listed in any order after those at or above 1%.
CosIng lists perfuming as well as preservative. That is a function label. It does not make propylparaben one of the fragrance substances that Annex III requires to be named above a set concentration.
A different salt: Sodium propylparaben is not this ingredient. The product section gives the index count and the categories.
These three names are all preservatives. They are not the same substance, and they do not share one EU maximum.
| Propylparaben | Methylparaben | Phenoxyethanol | |
|---|---|---|---|
| What it is | The propyl ester of 4-hydroxybenzoic acid. CAS 94-13-3. | The methyl ester. A shorter chain, and a different INCI. Methylparaben. | A glycol ether preservative, not a paraben. Phenoxyethanol. |
| EU preservative entry in force | Annex V entry 12a. 0.14% (as acid) for the sum of propylparaben, butylparaben, and their salts. Leave-on products for the nappy area of children under 3 are not a permitted use. | Annex V entry 12. 0.4% (as acid) for the ester alone, inside the 0.8% mixture cap. The 0.14% cap is not the methylparaben cap. | Annex V entry 29. The legal maximum is 1.0%. The SCCS 2016 opinion (SCCS/1575/16) addressed that maximum. That opinion is about phenoxyethanol. |
| 2020 CIR group conclusion | Included in the 20 parabens the Panel found safe when the sum of parabens in the formulation does not exceed 0.8%, within the uses and concentrations in that assessment. | The same group conclusion. The page for methylparaben carries that ingredient’s own assessment. | Not part of the parabens report. The phenoxyethanol page carries the CIR conclusion for that ingredient. |
The text in force is Annex V, entry 12a, of Regulation (EC) No 1223/2009, as inserted by Regulation (EU) No 1004/2014. It covers butyl 4-hydroxybenzoate and its salts and propyl 4-hydroxybenzoate and its salts, including the INCI names butylparaben, propylparaben, and their sodium and potassium salts. The maximum is 0.14% (as acid) for the sum of the individual concentrations. For mixtures with the substances in entry 12, the maximum is 0.8% (as acid), and within that mixture the sum of butylparaben, propylparaben, and their salts still does not exceed 0.14%. Entry 12a also says these substances are not to be used in leave-on products designed for application on the nappy area of children under three years of age. Leave-on products designed for children under three years of age carry the wording “Do not use on the nappy area”.
The 0.14% (as acid) maximum written by Regulation (EU) No 1004/2014 is the acid equivalent of 0.19% (as esters). That 0.19% figure is the level earlier SCCS opinions treated as acceptable for propylparaben and butylparaben together. It is not an affirmative safety conclusion of SCCS/1514/13. Recital 12 of Regulation (EU) No 1004/2014 records why the nappy-area condition uses under three years: the SCCS concern was leave-on products for the nappy area of children below six months, and products for infants are usually marketed for children under three.
The consolidation in force on 18 May 2026 was produced by later amendments, including Regulation (EU) 2026/78 and Regulation (EU) 2026/909. Those amendments changed other Annex V entries. They did not rewrite entry 12a. A draft notified to the WTO on 8 July 2026 would move butylparaben into a new entry 12b, with tighter conditions for children, and would leave propylparaben in entry 12a at 0.14%. That draft is not the regulation in force on 18 November 2026.
Regulation (EU) No 358/2014 added five other parabens to Annex II, the list of substances prohibited in cosmetic products: isopropylparaben, isobutylparaben, phenylparaben, benzylparaben, and pentylparaben. Propylparaben is not one of those five. CosIng lists isopropylparaben under Annex II entry 1374. That prohibition is a different ingredient.
The CIR amended assessment published in 2020 concluded that propylparaben is among 20 parabens safe in cosmetics in the practices of use and concentration described in that assessment, when the sum of parabens in a formulation does not exceed 0.8%. SCCS/1623/20, adopted on 30–31 March 2021, concluded that propylparaben is safe as a preservative up to 0.14%, and said the evidence was not sufficient to regard it as an endocrine disrupting substance. Those conclusions apply to the uses and concentrations the committees assessed.
The final amended report (panel meeting September 2019, published 2020) is the current CIR conclusion for this group. Propylparaben is one of the 20 parabens found safe in the practices of use and concentration described in the assessment when the sum of parabens in the formulation does not exceed 0.8%. Benzylparaben was the ingredient with insufficient data. The 9,034 VCRP uses in 2019, of which 7,520 are leave-on, are the frequency scope for propylparaben. A short label used with that conclusion, “Safe with Qualifications (SQ)”, points at this text. It is not the number in the rating section.
The Cosmetic Ingredient Review is supported by the cosmetics industry through the Personal Care Products Council. The 2016 concentration survey quoted in the report is a Council survey.
SCCS/1623/20, adopted on 30–31 March 2021, answered a question about endocrine-disrupting properties. The conclusion is that propylparaben is safe when used as a preservative in cosmetic products up to a maximum concentration of 0.14%. The committee also said the available data provide some indications for potential endocrine effects, and that the level of evidence is not sufficient to regard propylparaben as an endocrine disrupting substance, or to derive a toxicological point of departure from endocrine-disrupting properties for human health risk assessment. The mandate did not cover the environment.
This opinion is later than the CIR final amended report. It is not part of that CIR review.
The CIR amended assessment published in 2020 and SCCS/1623/20 are the conclusions for the cosmetic uses and concentrations those documents assessed. Those conclusions apply to the assessed uses. The cited data are not sufficient to quantify a pregnancy-specific risk, or a risk for breastfeeding. A product that stays inside the assessed uses is still the use those conclusions address. Someone who is pregnant or nursing and wants advice about a specific product should ask their own clinician.
The EU conditions in force are in the section above: Annex V entry 12a, a maximum of 0.14% (as acid) for propylparaben and butylparaben together, and no leave-on use on the nappy area of children under three.
Japan: The Japanese Standards for Cosmetics (MHLW Notification No. 331 of 2000), Appendix 3, limit p-hydroxybenzoic acid esters and their sodium salts to a total of 1.0 g per 100 g (1.0%) in all cosmetics. Propylparaben is one of those esters. That total is a different instrument from Annex V entry 12a. A 1.0% total under that standard is not the EU maximum.
Food and medicines, briefly: The CIR report records that US FDA treats propylparaben as GRAS as an antimicrobial in food (21 CFR 184.1670) and lists it as a synthetic flavouring (21 CFR 172.515). The report also notes inadequate data for general recognition of safety and effectiveness in diaper-rash drug products (21 CFR 310.545). That drug monograph is not the cosmetic Annex V entry. On the FDA list of select chemicals in the food supply under review, read 18 November 2026, propylparaben is listed as a food ingredient and a food-contact substance, at the review step Scientific Assessment, with review initiated on 4 March 2024. The page describes that table as the list under review as of 12 May 2026. The FDA states that it evaluates information about propylparaben as it becomes available. That list is about chemicals in the food supply. The GRAS listing in 21 CFR 184.1670 remains the food-use text cited above. The applicable EU legal restrictions remain those in Annex V entry 12a. The CIR 2020 assessment and SCCS/1623/20 provide separate scientific safety conclusions, not additional legal requirements.
Irritation, contact sensitisation, and immediate hypersensitivity are not the same event. The 2020 CIR report carries forward earlier rabbit-skin tests in which propylparaben at 10% was at most mildly irritating. That is an irritation result on rabbit skin at 10% of the test material, not a reading of a moisturiser, and not a sensitisation rate. The same report summarises human tests of product formulations containing 0.1% to 0.8% of one or two parabens, including propylparaben, as showing no significant irritation or sensitisation in those tests.
Contact sensitisation is what a patch test measures. The report summarises ESSCA data for 2009–2012: of 52,586 tests, the paraben mix gave positive reactions in fewer than 1% of tests, and of 2,362 TRUE Test readings the paraben mix gave positive reactions in 0.4% of tests. Those denominators are patch-tested patients and TRUE Test readings, not the general population, and the allergen is the paraben mix, not propylparaben tested alone. A positive patch test is not, by itself, a reaction every time that person uses a finished cosmetic. The report records the older observation that many patients sensitised by paraben medicaments, often on damaged skin, still use cosmetics that contain parabens without the same reaction. Dermatology texts call that the paraben paradox. A small number of published case reports describe allergic contact dermatitis in which a paraben was implicated. Those reports do not supply a rate for propylparaben in ordinary cosmetic use.
Immediate hypersensitivity, of the kind reported after some injected or oral medicines, is a different outcome again. The patch-test series above do not measure it, and they do not count reactions in people already known to be sensitised.
A higher score reflects the platform's rule-based combination of reported hazard classifications and selected regulatory restrictions. It does not measure the likelihood or severity of harm from a finished cosmetic product.
The base score is 3, determined by the highest-scoring hazard statement among H315, H319, and H335 reported in ECHA company notifications. These statements are not added together. One additional point is assigned under the platform's regulatory-restriction rule, resulting in a final score of 4/10. How this number is set.
Earlier SCCS opinions considered the combined use of propylparaben and butylparaben acceptable up to 0.19% (as esters). SCCS/1514/13, adopted in 2013, reiterated concerns about uncertainties in human exposure and toxicokinetics. The later SCCS/1623/20 opinion, adopted in 2021, concluded that propylparaben is safe as a preservative up to 0.14%, taking into account the available evidence on potential endocrine effects.
The background of SCCS/1514/13 quotes SCCS/1348/10 for that 0.19% sum. The 2013 conclusion says those concerns remain and are reinforced, and that adequate evidence had not been provided for the safe use of propylparaben or butylparaben in cosmetics. It asks for better data on human exposure, including children, and on the toxicokinetics of propylparaben and butylparaben in humans. Later SCCS opinions on butylparaben, SCCS/1651/23 and SCCS/1674/25 (final version 30 April 2025), assess butylparaben, including combined use in children from 6 months to 10 years in the 2025 opinion. They are not a replacement of the propylparaben conclusion in SCCS/1623/20. The 2025 opinion still describes the law then in force as entry 12a, at 0.14% (as acid) for butylparaben on its own or summed with propylparaben and its salts. Those butylparaben opinions are also later than the CIR review and are not part of it.
The substance evaluation conclusion for EC 202-307-7 (July 2023) records the Annex VI index number as a dash, and states that no entry in Annex VI of CLP is available. Read on 18 November 2026, CAS 94-13-3 has no EU harmonised classification. In the opinion adopted on 16 March 2023, the ECHA Committee for Risk Assessment concluded that propylparaben should not be classified for reproductive toxicity. That opinion did not add an Annex VI entry. CLP classification of the raw material does not apply to a finished cosmetic. Finished cosmetics are regulated by Regulation (EC) No 1223/2009.
PubChem CID 7175 is CAS 94-13-3. On 18 November 2026 its GHS section showed an ECHA C&L aggregation: 2,829 company reports from 29 notifications. Of those reports, 644 of 2,829 were reported as not meeting GHS hazard criteria. Among the 2,185 reports that carry hazard codes, the codes shown above 10% were H315 (63.6%), H319 (66.7%), and H335 (63.4%). PubChem states that this aggregation shows only codes above 10%. Those percentages are shares of the company reports that carry hazard codes. They are not the share of people who react, and they are not a concentration in a product. This aggregation is not an EU harmonised classification under CLP Annex VI.
The same PubChem section also showed a separate Danger list under the source name NITE-CMC. The substance id on that list is R02_A_062_METI,MOE, and the name is propyl 4-hydroxybenzoate, but the link is 20-meti-0089e. That page is flufenacet, CAS 142459-58-3. The statements on the list, H302, H317, H370, and H373, are the statements on the flufenacet page. They are not the NITE classification of CAS 94-13-3, and this page does not use them as propylparaben’s hazard statements.
20-meti-0062e is the FY2020 classification by METI and MOE for propyl 4-hydroxybenzoate, CAS 94-13-3, substance ID R02-A-062-METI, MOE. For human health, and not as a CLP Annex VI entry, acute oral toxicity and skin sensitisation are recorded as Not classified, as are skin irritation, serious eye damage/eye irritation, germ cell mutagenicity, and reproductive toxicity. Carcinogenicity is recorded as classification not possible. For specific target organ toxicity from a single exposure and from repeated exposure, on that same NITE page and not as a CLP Annex VI entry, the oral route is recorded as Not classified, and the class as a whole is classification not possible because the data for other routes were not sufficient.
The environmental classes are separate from those human-health classes. Short-term aquatic hazard is Category 2, H401, toxic to aquatic life. Long-term aquatic hazard is Category 2, H411, toxic to aquatic life with long lasting effects. These statements describe the substance. They are not a measure of a finished cosmetic.
Endocrine assays: Longer-chain parabens have been more active than methylparaben in estrogen-receptor assays. The SCCS/1623/20 conclusion quoted above is the committee’s current statement on whether that activity makes propylparaben an endocrine disrupting substance for the cosmetic assessment. The opinion is not part of the 2020 CIR review. Urinary biomonitoring studies summarised in the CIR report measure exposure. They are not a patch test, and they are not a clinical allergy rate. Separately, Belgium submitted a CLH proposal, opened for public consultation by ECHA on 11 April 2022, to classify propylparaben as Repr. 2, H361fd. The ECHA Committee for Risk Assessment adopted its opinion on 16 March 2023 and concluded that propylparaben should not be classified for reproductive toxicity. That conclusion is about reproductive toxicity only. It is not a finding that every other hazard class is clear, and it does not replace the SCCS statement on endocrine activity.
Absorption and hydrolysis: The CIR report summarises dermal studies in which permeability fell as the alkyl chain grew longer, methylparaben above ethylparaben above propylparaben above butylparaben, in frozen porcine skin. In one human-skin experiment cited there, a lotion with 0.2% propylparaben was applied to previously frozen skin; the report gives the penetrated share for the parabens in that test as a range from 0.007% ± 0.003 (butylparaben) to 0.057% ± 0.03 (methylparaben) at 36 hours after a single dose. Those percentages are shares of the applied dose in that experiment, not the concentration in a product. Esterases hydrolyse parabens to 4-hydroxybenzoic acid. In the plasma comparison the report cites, methylparaben and ethylparaben were stable, while propylparaben, butylparaben, and benzylparaben fell by 50% within 24 hours. Rat skin hydrolysed parabens orders of magnitude faster than human skin in the tissue-fraction work the report summarises. Those findings belong to those systems.
Inactive Ingredient Database: The same summary gives the FDA Inactive Ingredient Database’s recorded maximum potency for those dosage forms: 0.2 mg in a tablet and 0.2 mg/mL in an oral solution. That is the database’s recorded maximum potency for that dosage form, as stated in the CIR report read for this page on 18 November 2026. It is not a legal maximum, and it is not a safe daily intake. It is not a cosmetic concentration.
Look for the INCI name Propylparaben. Sodium Propylparaben is a different ingredient. Labels in other markets may also show 對羥基苯甲酸丙酯, 羟苯丙酯, プロピルパラベン, or 프로필파라벤. A position after the 1% line does not reveal the percentage. The EU conditions are a maximum of 0.14% (as acid) for propylparaben and butylparaben together, inside the wider 0.8% mixture rule, and a ban on leave-on use on the nappy area of children under three. The ingredient list of one product does not show whether that product meets those conditions.
The shorter ester. Together they are a common preservative pair. Methylparaben’s own EU maximum, 0.4% (as acid) for that ester, is not the 0.14% sum that applies to propylparaben and butylparaben.
A different preservative, sometimes in the same formula. EU Annex V entry 29 sets the legal maximum at 1.0%. That entry and the SCCS opinion on phenoxyethanol are not the paraben entries.
Butylparaben shares Annex V entry 12a with propylparaben. The 0.14% (as acid) maximum is the sum of the two and their salts, not a 0.14% allowance for each on top of the other. SCCS opinions from 2023 and 2025 on children are opinions on butylparaben. They do not rewrite the propylparaben conclusion.
Isopropylparaben, isobutylparaben, phenylparaben, benzylparaben, and pentylparaben are on Annex II. They are prohibited in cosmetic products. Seeing propylparaben on a list is not those ingredients.
On 18 November 2026, 3,296 products in the SkinSenseDiary product index list propylparaben (sodium propylparaben counted separately, 30 products). A product is counted once. The count is a usage figure for this index, not evidence of safety. Among products with a category, the most common were moisturisers (692), cleansers (207), face products (194), serums (179), sunscreens (170), treatments (158), face masks (136), and body lotions (134). 3,127 of 3,296 had a category.